ALSO NOTED: Critical Therapeutics shares surge; Orchid gets FDA OK; MedImmune pulls flyer; and much more...

> Shares of Critical Therapeutics got a boost today after the biotech announced a manufacturing deal for its asthma drug Zyflo, bringing it one step closer to its reintroduction to the market. Article

> India's Orchid Chemicals has received FDA approval of its ANDA for cephalexin capsules. Story

> MedImmune has pulled a flyer for FluMist after the FDA complained it contained misleading information. Story

> Auxilium Pharmaceuticals of Malvern, Pennsylvania, has raised $40.4 million in a private placement. Release

> Conforma has licensed an anti-cancer drug from Sumitomo Pharmaceuticals. Story

> Schering-Plough says its once-daily dose of Nasonex is safe and effective. Story

> Just weeks after a Supreme Court decision giving federal officials a green ligh to prosecute people for the use of medical marijuana, the Rhode Island legislature passed a bill allowing its use. Article

> Italy's Bioindustry Park Canavese announced six new biotechs in its Bioincubator. Release

And Finally... State workers in Georgia will soon face $100 co-pays for some branded drugs as employers continue to shift costs of ever-rising pharmaceuticals. Story

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.